Recent Press Releases

GenVec Announces Reduction in Workforce

GenVec Announces Reduction in Workforce GAITHERSBURG, Md., Sept. 25, 2012 GenVec, Inc. (Nasdaq: GNVC) announced today that it is lowering its operating costs to conserve capital including eliminating...

Hayfever vaccine study raises hopes for new allergy treatment

Hayfever vaccine study raises hopes for new allergy treatment Researchers are developing a new vaccine for hayfever which could be more effective, less invasive for patients and less expensive than...

Emory to receive $6 million for AIDS vaccine research

Emory to receive $6 million for AIDS vaccine research A $6 million grant from the Bill & Melinda Gates Foundation is part of the Collaboration for AIDS Vaccine Discovery (CAVD), a worldwide...

Developing an anthrax vaccine

Developing an anthrax vaccine 17 September 2012 A team of University scientists are leading new research to develop a vaccine against anthrax to help counteract the threat of bioterrorism. Working...

Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility

Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility On track to commence commercial production in third quarter 2012 By Sinovac Biotech Ltd. Published: Tuesday, Sep. 18,...

Novel Malaria Vaccine Collaboration Announced by Protein Potential LLC and Aduro BioTech Inc.

Novel Malaria Vaccine Collaboration Announced by Protein Potential LLC and Aduro BioTech Inc. ROCKVILLE, Md. & BERKELEY, Calif.--Protein Potential LLC and Aduro BioTech, Inc. have been awarded a...

Intercell's partner Biological E. Ltd. launches Japanese Encephalitis vaccine JEEV® in India

Intercell's partner Biological E. Ltd. launches Japanese Encephalitis vaccine JEEV® in India Novel vaccine to protect children and adults from Japanese Encephalitis (JE), manufactured by...

U.S. Vaccine Market is Expected to Reach USD 17.4 Billion by 2018: Transparency Market Research

U.S. Vaccine Market is Expected to Reach USD 17.4 Billion by 2018: Transparency Market Research ALBANY, New York, September 13, 2012 -- According to a new market report published by Transparency...

OHSU research helps explain why an AIDS vaccine has been so difficult to develop

OHSU research helps explain why an AIDS vaccine has been so difficult to develop 09/09/12 Portland, Ore. Research highlights why new methods developed at OHSU may be the most promising avenues for...

Abbott to Collaborate with Astellas in CMV Vaccine Trial

Abbott to Collaborate with Astellas in CMV Vaccine Trial ABBOTT PARK, Ill., Sept. 6, 2012 -- Abbott (NYSE: ABT) announced today that it has signed an agreement to collaborate with Astellas Pharma...

With No West Nile Vaccine in Sight, Self-Protection Is Key

With No West Nile Vaccine in Sight, Self-Protection Is Key (Sep. 4, 2012) — As this year's threat from the West Nile virus continues, one infectious diseases expert at the University of...

ImmunoCellular Therapeutics Completes Enrollment of Phase II Trial of ICT-107 in Glioblastoma

ImmunoCellular Therapeutics Completes Enrollment of Phase II Trial of ICT-107 in Glioblastoma ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced today that the...

Cancer 'turns off' important immune cells, complicating experimental vaccine therapies

Cancer 'turns off' important immune cells, complicating experimental vaccine therapies New research published in the Journal of Leukocyte Biology suggests monocyte-derived dendritic cells may...

ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease

ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease CAMBRIDGE, Mass., September 4, 2012 – ImmusanT announced today that it has initiated clinical trials in New...

Soligenix Announces Positive Phase 1B Clinical Results with RiVax™, its Vaccine Against Ricin Toxin Exposure

Data show that RiVax™ formulated with adjuvant induces robust immune responses in human volunteers PRINCETON, N.J., Aug. 30, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or...

Soligenix Announces Positive Phase 1B Clinical Results with RiVax™, its Vaccine Against Ricin Toxin Exposure

Soligenix Announces Positive Phase 1B Clinical Results with RiVax™, its Vaccine Against Ricin Toxin Exposure Data show that RiVax™ formulated with adjuvant induces robust immune responses...

NIH scientists map first steps in flu antibody development

NIH scientists map first steps in flu antibody development Knowing origin of broadly neutralizing antibodies could aid universal flu vaccine design National Institutes of Health scientists have...

Pascal Soriot appointed Chief Executive Officer of AstraZeneca

Pascal Soriot appointed Chief Executive Officer of AstraZeneca Tuesday, 28 August 2012 AstraZeneca today announced that Pascal Soriot has been appointed as the company's Chief Executive Officer....

Compound discovered that boosts effect of vaccines against HIV and flu

Compound discovered that boosts effect of vaccines against HIV and flu Novel vaccine additive to enhance the body's immune response shows promise in mice Oxford University scientists have...

PATH Malaria Vaccine Initiative (MVI) Creates New Central "Reference" Lab, Standardizing Ability to Measure Performance of Malaria Vaccine Formulations

PATH Malaria Vaccine Initiative (MVI) Creates New Central "Reference" Lab, Standardizing Ability to Measure Performance of Malaria Vaccine Formulations MVI, International AIDS Vaccine...